Tourmaline Bio Ownership
| TRML Stock | 18.48 0.12 0.65% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 25 M | Current Value 26 M | Avarage Shares Outstanding 7.8 M | Quarterly Volatility 10.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tourmaline | Build AI portfolio with Tourmaline Stock |
Tourmaline Stock Ownership Analysis
About 22.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.7. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tourmaline Bio recorded a loss per share of 3.23. The entity last dividend was issued on the 20th of October 2023. The firm had 1:10 split on the 20th of October 2023. To find out more about Tourmaline Bio contact Sandeep MD at 646 481 9832 or learn more at https://www.tourmalinebio.com.Besides selling stocks to institutional investors, Tourmaline Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tourmaline Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tourmaline Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tourmaline Bio Quarterly Liabilities And Stockholders Equity |
|
About 22.0% of Tourmaline Bio are currently held by insiders. Unlike Tourmaline Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tourmaline Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tourmaline Bio's insider trades
Tourmaline Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tourmaline Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tourmaline Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tourmaline Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tourmaline Bio Outstanding Bonds
Tourmaline Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tourmaline Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tourmaline bonds can be classified according to their maturity, which is the date when Tourmaline Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TOTAL CAP 3883 Corp BondUS89152UAH59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| TOTAL CAPITAL INTERNATIONAL Corp BondUS89153VAQ23 | View | |
| US89157XAA90 Corp BondUS89157XAA90 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| TOTAL CAPITAL INTERNATIONAL Corp BondUS89153VAX73 | View | |
| TOTAL CAPITAL INTERNATIONAL Corp BondUS89153VAV18 | View |
Tourmaline Bio Corporate Filings
8K | 9th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify | |
| 21st of April 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.